Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Quercetin and Ng-Nitroarginine Methyl Ester

Research Papers that Mention the Interaction

Also, L-NAME (100 μM), a non-selective NO synthase (NOS) inhibitor, blocked the effects of quercetin on pacemaker activity and quercetin stimulated cGMP production.
Cellular Physiology and Biochemistry  •  2015  |  View Paper
Thus, quercetin administration counteracts l-NAME effects on NO bioavailability determinants in vivo, essentially through controlling NOX-mediated superoxide anion production.
Archives of biochemistry and biophysics  •  2018  |  View Paper
L-NAME , indomethacin, and ODQ treatment also decreased the potency of quercetin.
Journal of Asian natural products research  •  2018  |  View Paper
Administration of L-NAME prior to administration of quercetin and rutin, significantly reduced the cerebroprotection offered by quercetin and rutin.
European review for medical and pharmacological sciences  •  2013  |  View Paper
The vasorelaxant effect of quercetin was partially but not significantly (p > 0.05) inhibited by L-NAME (100 μM) or indomethacin (10 μM), suggesting that the vasorelaxant effect of the flavonoid was unlikely to be mediated via endothelium-dependent relaxing factor (EDRF), or through prostacyclin (PGI2) pathways.
Cardiovascular journal of Africa  •  2010  |  View Paper
Nw‐nitro‐L‐arginine methyl ester (l‐NAME, 10 mmol/L) significantly attenuated the vasodepressor effects of quercetin and ascorbic acid, raising the responses to PE to a level similar to that observed in the control SHR tissues.
Clinical and experimental pharmacology & physiology  •  2006  |  View Paper
Furthermore, both nitro-L-arginine-methyl ester (L-NAME, 100 microM) and indomethacin (10 microM) markedly attenuated the vasorelaxant responses following quercetin application.
Vascular pharmacology  •  2004  |  View Paper
The antiperistaltic effect of quercetin was partially prevented by apamin (0.5 µmol/l), N-nitro-L-arginine methylester (100 µmol/l) and naloxone (0.5 µmol/l), whereas the effect of genistein was hardly affected by these drugs.
Pharmacology  •  2003  |  View Paper
Quercetin produced a similar relaxation, which was also abolished by L-NAME.
Life sciences  •  2001  |  View Paper
Inhibiting mitoKATPchannels by 100 μM 5-hydroxydecanoate and blocking NO system by 100 μM L-NAME reversed the cardioprotective effects of Que.
Cell journal  •  2021  |  View Paper
Show More